Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yeah, thanks I Inanaco, I guess I was focusing on the last line of Rays post discussing the Glycans Platform..........
"""Searching out more and more facets of how Mabs bind to their targets.
More glycans work to come, methinks."""
Me thinks so too, but makes it impossible to put timelines to what the finished article will compromise and just how much work we still have to arrive there. Hence the need for updates, and I was delighted at least to hear CH re-iterating the MOD1 trial date by end H1 2020.
Ray , you have posted a few schedules on the news we might expect at any given time, the last one some months ago, I wonder if you could do another one just to remind us of what a positive pipeline we have, and where we stand now, which i guess hasn"t changed too much but as time moves on could be very close to filtering through, not to mention the current plans for the SCIB1 trial. Whilst so much uncertainty in our lives has been adressed this past week, almost dare I say a return to a good feel factor, we haven"t had for too long, it would be a tremendous time for Scancell to release good news, not withstanding news can only be released on the current situations and in no way am I suggesting they have held on to releasing news for such a time.
Apologies to all for bringing up the subject of politics last week, I didn"t want to debate whether capitalism or communism were right for us all, but religion is IMHO a very different proposition, we hear it pressed home at all sporting events and everyday life, and I have strong feeling about cutting racism from all sectors of our lives, and I just had no hang ups stating how hateful it all is and has no place in our society.
To close on that the people of the North reiterating those very points will always mean so much to me, having spent so many years living amongst them, very proud of them and hope they can get everything they wished for this time round.
So just IMHO yes I do fancy news before the end of the year, and dependant on what it is the pathway back to 10p could be a very short one, given the possibilities our pipelines express.
To a new week, some good news for us, and an end to a very hateful envirement as we wlcome "Extinction Rebellion"" to the fray, lol.
How do you ever in the moving world of Science get to the point when you have a ready to go Commercial Product?
Once manufactured and tested via toxicology ...
SCIB1
SCIB2
Modi1
that is then the "finished article" ......... then the ""serious"" expenditure starts
which is why getting the basics "right" is so important
Scancell is all about "Binding" ... mentioned this before, we are Experts in this field
So hard to put timelines to so many different activities, which lets face it is why Scancell didn"t at the AGM. How do you ever in the moving world of Science get to the point when you have a ready to go Commercial Product?
It's not just the amount of the work, it's how well directed it is.
So, the Mab bound well to 1 target but not others. Why?
Well, this research gives her the answer.
Searching out more and more facets of how Mabs bind to their targets.
More glycans work to come, methinks.
More evidence too of the enormous amount of work Lindy does. Hopefully we will get to see that translated into news and inflection based too. St ill fancy some decent news before year end.
The article also shows how important the shape of molecular structures are in the binding process.
Have a look at Figure 6 towards the end of the article.
Good find moonparty
It looks to be a joint effort between 3 Melbourne Unis, Nottingham Uni and ,of course, Scancell.
It's more work on Glycans and in particular how a particular Mab (ch28/11) binds to a particular target (SSEA-4).
They have discovered that the sialic acid in the target plays a key role in the binding.
"These high-resolution views of how a glycolipid interacts with an antibody may help advance a new class of cancer-targeting immunotherapy."
Lindy Durrant co-author on this. Seems to be links with RMIT University, Australia ?
http://m.jbc.org/content/early/2019/12/12/jbc.RA119.011518.abstract